Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.

News

BWXT Medical and TRIUMF Execute Agreement for Manufacture of High Purity Ac-225 Based Products

13 June 2022

BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. and TRIUMF, Canada’s particle accelerator centre, have executed a licensing and services agreement that strengthens their existing partnership for the production of medical isotopes.


BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225

16 September 2021

(OTTAWA, Ontario – September 16, 2021) – BWX Technologies, Inc. (NYSE: BWXT) announced today that its BWXT Medical Ltd. subsidiary (BWXT Medical) has entered into an agreement with Bayer AG (Bayer) to develop Actinium-225 (Ac-225) supply and further partnering opportunities on finished products as both companies broaden their respective commercialization strategies for targeted radionuclide therapies (TRTs) and other innovative products.


BWXT Medical Enters into a New Long-Term Agreement with Boston Scientific

10 May 2021

(Ottawa, Ontario – May 10, 2021) – BWXT Medical Ltd. (BWXT Medical) announced today that it has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere™ Y-90 Glass Microspheres for Boston Scientific, a leading global medical device company.


BWXT Names Nuclear Medicine Business as BWXT Medical

01 February 2021

(LYNCHBURG, Va. – Feb. 1, 2021) – BWX Technologies, Inc. (NYSE: BWXT) today announced that its subsidiary BWXT ITG Canada, Inc., a nuclear medicine company, has been renamed BWXT Medical Ltd. (BWXT Medical), in order to better align with the company’s products, customer base and strategy.


OPG and BWXT Make Significant Progress in Production of Life-Saving Medical Isotope at Darlington Nuclear Generating Station

24 September 2020

Darlington to become first large-scale nuclear station to produce molybdenum-99.